The primary focus Patient-Derived Xenograft (PDX) Core is to develop, and provide to the Baylor PDX community, computational and bioinformatics infrastructure to support large scale generation, ...

The approval is based on the results from the CheckMate-9DW trial, in which 85 percent of patients in the comparator arm were treated with lenvatinib and 15 percent were treated with sorafenib ...